Trials / Unknown
UnknownNCT06299982
An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO
A Multicenter,Randomized,Phase 3 Trial to Evaluate the Efficacy and Safety of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Patients With Moderate-to-Severe Plaque Psoriasis
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 750 (estimated)
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examin the efficacy and safety of the study drug recombinant anti-IL-17A humanized monoclonal antibody in Chinese participants with moderate-to-severe plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 608 Q2W | 608 160 mg at week 0 + 80 mg Q2W (5 cycles) |
| DRUG | 608 Q4W | 608 160 mg Q4W (3 cycles) |
Timeline
- Start date
- 2024-05-15
- Primary completion
- 2025-01-30
- Completion
- 2025-03-20
- First posted
- 2024-03-08
- Last updated
- 2024-03-08
Source: ClinicalTrials.gov record NCT06299982. Inclusion in this directory is not an endorsement.